Cover Image

Potential Mechanism of Fatigue Induction and Its Management by JAK Inhibitors in Inflammatory Rheumatic Diseases

Anna Felis-Giemza,1 Magdalena Massalska,2 Leszek Roszkowski,3 Katarzyna Romanowska-Próchnicka,4 Marzena Ciechomska2 1Biologic Therapy Center, National Institute of Geriatrics, Rheumatology, and Rehabilitation (NIGRiR), Warsaw, Poland; 2Department of Pathophysiology and Immunology, National Institut...

Full description

Saved in:

Bibliographic Details
Main Authors:	Felis-Giemza A (Author), Massalska M (Author), Roszkowski L (Author), Romanowska-Próchnicka K (Author), Ciechomska M (Author)
Format:	Book
Published:	Dove Medical Press, 2023-09-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

User's guide to JAK inhibitors in inflammatory bowel disease
by: Ted A. Spiewak, DO, et al.
Published: (2022)

Epigenetic Modulation as a Therapeutic Prospect for Treatment of Autoimmune Rheumatic Diseases
by: Marzena Ciechomska, et al.
Published: (2016)

Janus kinase (JAK) inhibitors in the treatment of neoplastic and inflammatory disorders
by: Robert Roskoski, Jr
Published: (2022)

JAK Inhibitors in Psoriatic Disease
by: Megna M, et al.
Published: (2023)

Reducing fatigue in pediatric rheumatic conditions: a systematic review
by: K. Kant-Smits, et al.
Published: (2021)

Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis
by: Meyer Debra M, et al.
Published: (2010)

JAK-STAT pathway inhibitors in dermatology
by: Hélio Amante Miot, et al.
Published: (2023)

Tofacitinib and newer JAK inhibitors in inflammatory bowel disease-where we are and where we are going
by: Eleanor Liu, et al.
Published: (2022)

Ileocolonic-Targeted JAK Inhibitor: A Safer and More Effective Treatment for Inflammatory Bowel Disease
by: Vipul Yadav, et al.
Published: (2022)

JAK inhibitors: a potential treatment for JDM in the context of the role of interferon-driven pathology
by: Meredyth G. Ll Wilkinson, et al.
Published: (2021)

A Comprehensive Overview of Globally Approved JAK Inhibitors
by: Ahmed M. Shawky, et al.
Published: (2022)

JAK inhibitors in systemic juvenile idiopathic arthritis
by: Tingyan He, et al.
Published: (2023)

Janus Kinase (JAK) Inhibitors in Rheumatoid Arthritis
by: Vishal R. Tandon, et al.
Published: (2022)

OA2-2 Jak inhibitors employ novel mechanisms to block reservoir seeding and HIV persistence
by: C. Gavegnano, et al.
Published: (2017)

Potential applications of JAK inhibitors, clinically approved drugs against autoimmune diseases, in cancer therapy
by: Xiao-Huan Wei, et al.
Published: (2024)

Metabolic syndrome in inflammatory rheumatic diseases
by: G. La Montagna, et al.
Published: (2011)

Effectiveness of Soluble CTLA-4-Fc in the Inhibition of Bone Marrow T-Cell Activation in Context of Indoleamine 2.3-Dioxygenase (IDO) and CD4+Foxp3+ Treg Induction
by: Massalska M, et al.
Published: (2022)

Association of digital measures and self-reported fatigue: a remote observational study in healthy participants and participants with chronic inflammatory rheumatic disease
by: Chaitra Rao, et al.
Published: (2023)

Clinical utility of the oral JAK inhibitor tofacitinib in the treatment of rheumatoid arthritis
by: Cutolo M, et al.
Published: (2013)

Systemic Treatment of Psoriasis with JAK Inhibitors: A Review
by: Amanda Kvist-Hansen, et al.
Published: (2019)

Boxed warnings for dermatologic JAK inhibitors: are they standardized worldwide?
by: Shayla Nguyen, et al.
Published: (2024)

Cardiovascular safety, cancer and Jak-inhibitors: Differences to be highlighted
by: Maurizio Benucci, et al.
Published: (2022)

Recent advances in JAK inhibitors for the treatment of metabolic syndrome
by: Debora Collotta, et al.
Published: (2023)

Monoamine Oxidase Inhibitors: A Review of Their Anti-Inflammatory Therapeutic Potential and Mechanisms of Action
by: Mahyar Ostadkarampour, et al.
Published: (2021)

Which is the ideal JAK inhibitor for alopecia areata - Baricitinib, tofacitinib, ritlecitinib or ifidancitinib - Revisiting the immunomechanisms of the JAK pathway
by: Kabir Sardana, et al.
Published: (2023)

The mediterranean diet model in inflammatory rheumatic diseases
by: P. Spinella, et al.
Published: (2011)

JAK Inhibitors as Potential Therapeutic Strategy for the Dilemma of Psoriasis Concurrent with Dermatomyositis in the SARS-CoV-2 Era
by: Xu Q, et al.
Published: (2023)

The effect of food on the pharmacokinetics of WXFL10203614, a potential selective JAK1 inhibitor, in healthy Chinese subjects
by: Kai Huang, et al.
Published: (2022)

JAK inhibitors: a promising direction for treating Rheumatoid Arthritis
by: Pelechas Eleftherios
Published: (2017)

Efficacy and Safety of JAK1 Inhibitor Abrocitinib in Atopic Dermatitis
by: Helena Iznardo, et al.
Published: (2023)

JAK inhibitors: an evidence-based choice of the most appropriate molecule
by: Luca Antonioli, et al.
Published: (2024)

Characterization of Selective and Potent JAK1 Inhibitors Intended for the Inhaled Treatment of Asthma
by: Nilsson M, et al.
Published: (2022)

Risk of herpes zoster associated with JAK inhibitors in immune-mediated inflammatory diseases: a systematic review and network meta-analysis
by: Qingling Xu, et al.
Published: (2023)

Targeting Cytokine Signaling and Lymphocyte Traffic via Small Molecules in Inflammatory Bowel Disease: JAK Inhibitors and S1PR Agonists
by: Tamara Pérez-Jeldres, et al.
Published: (2019)

Successful Treatment of Granulomatous Rosacea by JAK Inhibitor Abrocitinib: A Case Report
by: Ren M, et al.
Published: (2023)

Molecular Mechanism of Neuronal Plasticity: Induction and Maintenance of Long-Term Potentiation in the Hippocampus
by: Eishichi Miyamoto
Published: (2006)

Anti-Rheumatic Drugs as Potential Anti-inflammatory, Immunomodulatory Agents against COVID-19: A Systematic Review
by: Reza Sinaei, et al.
Published: (2021)

A Comprehensive Literature Review of JAK Inhibitors in Treatment of Alopecia Areata
by: Dillon KAL
Published: (2021)

Treatment of Atopic Dermatitis Using JAK Inhibitors: A Systematic Review
by: Stefan Siedlikowski, et al.
Published: (2019)

Refractory granuloma faciale successfully treated with adjunct topical JAK inhibitor
by: Ailynna Chen, MPH, et al.
Published: (2023)